Women with Alzheimer’s disease experience faster mental decline than men with the same condition, according to British researchers. This difference in cognitive functioning was apparent even in individuals at the same stage of the disease.
The meta analysis of 15 published studies revealed that men with Alzheimer’s disease consistently performed better than women with the disease across the five cognitive areas examined. The cognitive areas studied were semantic, which includes participants’ understanding of meanings and concepts, nonsemantic, verbal, visuospatial, which includes participants’ perceptions of spatial relationships, and memory. The most significant difference between the performance of men and women was seen in tests that measured semantic or memory ability. The performance gap between the sexes was seen even when researchers controlled for age, education level, and severity of dementia.
Researchers were unsure what caused this discrepancy, but discussed some possible explanations. “There has been some previous, but limited, evidence that females with Alzheimer’s deteriorate faster than males in the earlier stages of the disease. And possible explanations are for a hormonal influence, possibly due to estrogen loss in women or perhaps a greater cognitive reserve in males which provides protection against the disease process,” said Keith Laws a psychology professor at the University of Hertfordshire in the university’s press release. “But further studies to examine sex differences with the disease are needed to provide greater clarity on these issues.”
Read a press release about this Alzheimer's disease study or review the complete findings titled Greater Cognitive Deterioration In Women Than Men With Alzheimer's Disease: A Meta Analysis.
All About Alzheimer’s: Slowing the Aging Process, Digital Health Apps, Sense of Smell as Alzheimer’s Indicator
Scientists have developed an experimental medication that aids in ameliorating the effects of Alzheimer’s disease by slowing down the aging process. T...
President Ronald Reagan designated November as National Alzheimer’s Awareness Month in 1983 – at a time in the United States when fewer than 2 million...
Health and Wellness, Medication Management, Medication Technology & Informatics, Memory Care Best Practices and Research
The University of North Carolina at Chapel Hill has been awarded a $3.4 million grant from the National Institute on Aging to study the use of antipsy...
End of Life, Medication Management, Memory Care Best Practices and Research
Total health spending for people with dementia was more than a quarter-million dollars per person during the last five years of life, which is approxi...
The Pan American Health Organization, which is the World Health Organization’s agency for the Americas, has adopted a regional plan of action on demen...
Facts and Figures, Health and Wellness, Medication Management, Memory Care Best Practices and Research, Memory Care Education, Reports
A large, national clinical trial to study the effect of resveratrol long-term in people with mild to moderate Alzheimer’s disease found that a biomark...
All About Alzheimer’s: Receptor Drug Success, Gene Signatures, Type 2 Diabetes, and Expanding Waistlines
There are currently five medications approved by the FDA to treat Alzheimer’s disease but these drugs mask the symptoms rather than stop the disease f...
End of Life, Engage, Managed Risk, Membership, Memory Care Best Practices and Research, Memory Care Education
The Alzheimer’s Foundation of America has announced that National Memory Screening Week will take place the first week of November and participating s...
Facts and Figures, Memory Care Best Practices and Research, Memory Care Education, Reports
There are currently about 46.8 million people around the globe living with dementia with those figures expected to nearly double every 20 years, find...
The Dementia Action Alliance has a released a new report outlining language use related to dementia, noting that these words currently used to describ...